Literature DB >> 21748522

Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients.

T D Shi1, J M Zhang, X F Wang, M Chen, H Sun, C B Chen, H Ren.   

Abstract

iNKT cells are relatively abundant in the liver, which suggests that they may play important roles in the clearance of invading foreign pathogens such as hepatitis B virus. In this study, we investigated the frequencies, functions and PD-1 expression of peripheral iNKT cells from HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment with Telbivudine. Results demonstrated that as compared with the healthy donors, the peripheral iNKT cells from these patients existed at lower frequencies, displayed impaired capabilities to produce IFN-γ and expressed higher PD-1. Antiviral treatment with Telbivudine significantly increased IFN-γ production by iNKT cells, which may be associated with the decreased PD-1 expression as manifested by blocking experiments. Our study suggested that iNKT cells played an important role in the chronicity of HBV infection and antiviral therapy with Telbivudine could restore at least in part the impaired host immune response in the HBeAg-positive CHB patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748522     DOI: 10.1007/s10238-011-0151-8

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  32 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

Review 2.  The composition of intrahepatic lymphocytes: shaped by selective recruitment?

Authors:  Katja Klugewitz; David H Adams; Masashi Emoto; Katharina Eulenburg; Alf Hamann
Journal:  Trends Immunol       Date:  2004-11       Impact factor: 16.687

3.  PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

Authors:  Holly Maier; Masanori Isogawa; Gordon J Freeman; Francis V Chisari
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 4.  NKT cells: T lymphocytes with innate effector functions.

Authors:  Luc Van Kaer
Journal:  Curr Opin Immunol       Date:  2007-04-10       Impact factor: 7.486

5.  Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application?

Authors:  Henry Radziewicz; Holly L Hanson; Rafi Ahmed; Arash Grakoui
Journal:  Gastroenterology       Date:  2008-05-16       Impact factor: 22.682

Review 6.  Immunology of hepatitis B infection.

Authors:  Maria-Christina Jung; Gerd R Pape
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

7.  Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy.

Authors:  Woo-Sung Chang; Ji-Yeon Kim; Yeon-Jeong Kim; Yun-Sun Kim; Jung-Mi Lee; Miyuki Azuma; Hideo Yagita; Chang-Yuil Kang
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis.

Authors:  Y Yoshiga; D Goto; S Segawa; Y Ohnishi; I Matsumoto; S Ito; A Tsutsumi; M Taniguchi; T Sumida
Journal:  Int J Mol Med       Date:  2008-09       Impact factor: 4.101

9.  PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.

Authors:  Guoping Peng; Shuping Li; Wei Wu; Xufei Tan; Yiqiong Chen; Zhi Chen
Journal:  Mol Immunol       Date:  2007-09-14       Impact factor: 4.407

10.  Functionally distinct NKT cell subsets and subtypes.

Authors:  Ken-Ichiro Seino; Masaru Taniguchi
Journal:  J Exp Med       Date:  2005-12-19       Impact factor: 14.307

View more
  10 in total

1.  Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses.

Authors:  Nan Meng; Xiao Gao; Wei Yan; Mi Wang; Ping Liu; Xiao-Dan Lu; Shu-Juan Zhang; Ya-Qi Lu; Wang-Xian Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

2.  NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Authors:  L Bergantini; P Cameli; M d'Alessandro; C Vagaggini; R M Refini; C Landi; M G Pieroni; M Spalletti; P Sestini; E Bargagli
Journal:  Clin Exp Med       Date:  2019-09-04       Impact factor: 3.984

3.  Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.

Authors:  Xihua Fu; Haibo Lou; Fang Chen; Xueping Gao; Zhanzhou Lin
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

4.  Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.

Authors:  Cheng-Zhong Li; Jing-Jing Hu; Jian-Ya Xue; Wei Yin; Ya-Yun Liu; Wen-Han Fan; Hao Xu; Xue-Song Liang
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 5.  Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment.

Authors:  Agnieszka Lawrenczyk; Seil Kim; Xiangshu Wen; Ran Xiong; Weiming Yuan
Journal:  Pathogens       Date:  2014-07-03

6.  Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus Infection.

Authors:  Haoxiang Zhu; Yongmei Zhang; Hongyan Liu; Yijun Zhang; Yaoyue Kang; Richeng Mao; Feifei Yang; Dapeng Zhou; Jiming Zhang
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

7.  Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B.

Authors:  Ye Zhang; Wei-Lu Zhang; Xiao-Wen Pang; Lin-Xu Wang; Xin Wei; Chang-Xing Huang; Xue-Fan Bai; Shuai Han; Lin-Na Liu; Jian-Qi Lian
Journal:  Virol J       Date:  2017-03-09       Impact factor: 4.099

8.  Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.

Authors:  Yanhua Zheng; Zemin Huang; Xianhua Chen; Yi Tian; Jun Tang; Yi Zhang; Xiaomin Zhang; Jijun Zhou; Qing Mao; Bing Ni; Qinghong Wang; Yuzhang Wu
Journal:  Mediators Inflamm       Date:  2012-04-11       Impact factor: 4.711

9.  Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.

Authors:  Shaohang Cai; Jiawei Cao; Tao Yu; Muye Xia; Jie Peng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

10.  Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study.

Authors:  Zhaoping Yan; Bing Qiao; Haifeng Zhang; Yanling Wang; Wei Gou
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.